Phase
Condition
Opioid Use Disorder
Stimulant Use Disorder
Alcohol Dependence
Treatment
Sleep extension and advance
Regular sleep duration and timing
Clinical Study ID
Ages 18-24 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
18-24 years of age;
NIAAA criteria for past-month high-risk drinking (i.e., ≥ 4 drinks/day or ≥ 8/weekfor women, ≥ 5 drinks/day or ≥ 15/week for men);
short and late sleep (weekday sleep duration ≤ 7.5 hours and bedtime ≥ 24:00 (midnight); n=60) or long and early sleep (weekday sleep duration > 7.5 hours andbedtime ≤ 24:00 (midnight); n=30);
at least moderate lifetime exposure to stressors (≥ 2 events on the 20-item AdultStress and Adversity Inventory-Screener);
not currently in high school; and
English language fluency.
Exclusion
Exclusion Criteria:
Severe alcohol use disorder (AUD) and/or substance use disorder (SUD), defined as ≥6AUD/SUD criteria in the Diagnostic and Statistical Manual-5;
acute alcohol intoxication on the days of the laboratory post-intensive visits,operationalized as a blood alcohol concentration of .02 or higher duringBreathalyzer saliva screen;
current clinician-provided diagnosis of narcolepsy or idiopathic hypersomnia;
lifetime diagnosis of bipolar or schizophrenia spectrum disorder;
certain medical conditions (e.g., serious neurological disorder, heart failure orserious trouble, history of head injury with unconsciousness > 5 minutes);
conditions that are contraindicated for MRI (e.g., ferrous metal in the body);
positive screen for participant-reported eye disease, epilepsy, or photosensitizingmedications that are contraindicated during the manipulation condition when brightlight is administered (e.g., psychiatric neuroleptic drugs [e.g., phenothiazine],psoralen drugs, antiarrhythmic drugs [e.g., amiodarone], antimalarial andantirheumatic drugs, porphyrin drugs used in photodynamic treatment of skindiseases);
use of melatonin if participant is not willing to discontinue use for the durationof the study.
We will schedule around (i.e., delay appointments as needed) to avoid the timeframe of the following events:
urgent suicide risk, defined by moderate/severe risk per CSSR and cliniciandetermination that current risk requires immediate action;
travel across two or more time zones within the month prior to the overnight studyvisits.
begin/end a prescribed medication within 2 months of the observational study;
medication dose changes within the timeframe calculated as 5x the drug's half-life [the time to reach pharmacokinetic steady-state] before the initiation of theobservational or experimental studies;
participant-anticipated changes in prescribed medications or medication dosingduring the observational or experimental studies.;
current symptoms of an airborne infectious illness (e.g., COVID) prior to laboratoryvisits.
Participants with positive breathalyzer screen (blood alcohol level > .02) will be rescheduled for an alternative overnight visit date.
Study Design
Study Description
Connect with a study center
Oregon Sleep Lab
Eugene, Oregon 97403
United StatesSite Not Available
Oregon Sleep Lab
Eugene 5725846, Oregon 5744337 97403
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.